Abstract
To the Editor: In their article about 3261 aspirin-treated patients enrolled in the Clopidogrel for the High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial,1 Eikelboom et al suggest that incomplete inhibition of platelet thromboxane biosynthesis by aspirin is associated with heightened cardiovascular risk on the basis of the finding that high urinary concentrations of the thromboxane A2 metabolite, 11-dehydrothromboxane B2, were associated with increased risk for cardiovascular events. Among the limitations of this study that have been acknowledged by the authors, the choice of urinary 11-dehydrothromboxane B2 …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
